Analyst Price Targets — TRVI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 1:50 pm | — | Morgan Stanley | $23.00 | $18.23 | TheFly | Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley |
| August 7, 2026 12:11 pm | — | Oppenheimer | $25.00 | $18.25 | TheFly | Trevi Therapeutics price target raised to $25 from $24 at Oppenheimer |
| August 7, 2026 10:25 am | Ryan Deschner | Raymond James | $40.00 | $18.50 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $40 at Raymond James |
| July 20, 2026 8:23 pm | — | BMO Capital | $36.00 | $16.77 | TheFly | Trevi Therapeutics initiated with an Outperform at BMO Capital |
| July 20, 2026 10:47 am | Brandon Folkes | H.C. Wainwright | $24.00 | $19.07 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $24 at H.C. Wainwright |
| May 8, 2026 11:34 am | Annabel Samimy | Stifel Nicolaus | $30.00 | $14.05 | TheFly | Trevi Therapeutics price target raised to $30 from $18 at Stifel |
| May 6, 2026 11:15 am | — | Morgan Stanley | $20.00 | $14.66 | TheFly | Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley |
| December 19, 2025 12:50 pm | — | Stifel Nicolaus | $18.00 | $12.19 | TheFly | Trevi Therapeutics price target raised to $18 from $15 at Stifel |
| November 19, 2025 10:23 am | Roanna Ruiz | Leerink Partners | $16.00 | $11.31 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners |
| November 14, 2025 1:19 pm | Judah Frommer | Morgan Stanley | $19.00 | $11.68 | TheFly | Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley |
Latest News for TRVI
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management…
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market…
Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRVI.
U.S. House Trading
No House trades found for TRVI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.